SCHEMBL7201041

SCHEMBL7201041

CCN(N)C(Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
MAPT P10636 2/20 0.61
POLB P06746 2/20 0.61
KMT2A Q03164 2/20 0.61
APAF1 O14727 1/20 0.61
RECQL P46063 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MEN1 O00255 1/20 0.61
LMNA P02545 1/20 0.61
MPO P05164 1/20 0.61
TSHR P16473 1/20 0.61
BLM P54132 1/20 0.61
PMP22 Q01453 1/20 0.61
HIF1A Q16665 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.59
HTR2A P28223 2/20 0.53
ADRB1 P08588 1/20 0.52
HTR1A P08908 1/20 0.52
ADRA2A P08913 1/20 0.52
SLC6A2 P23975 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7766717 0.87 KDM4E (0.55) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL7766713 0.87 KDM4E (0.55) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL30735894 0.87 KDM4E (0.64) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL29212839 0.86 KDM4E (0.63) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL3855614 0.84 KDM4E (0.68) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL3855611 0.84 KDM4E (0.68) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL29212821 0.84 KDM4E (0.68) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL29170027 0.84 KDM4E (0.60) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL31520102 0.84 KDM4E (0.60) KDM4EMAPTPOLBKMT2AAPAF1
SCHEMBL9960361 0.84 KMT2A (0.60) KDM4EMAPTPOLBKMT2AAPAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103282375-A Peptide scaffold design BIONOR IMMUNO AS 2013-09-04 CN disclosed
US-20030195144-A1 Antimicrobial compounds and formulations LYTIX BIOPHARMA AS (NO) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195144-A1 Antimicrobial compounds and formulations LPO, CLPTM1, VIP KDM4E 4487/4885MAPT 4459/4885POLB 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.